The vasomotor menopausal symptoms (vms) treatment global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Vasomotor Menopausal Symptoms (VMS) Treatment Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The vasomotor menopausal symptoms (vms) treatment market size has grown strongly in recent years. It will grow from $16.6 billion in 2023 to $17.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to hormone replacement therapy (hrt), menopause awareness, pharmaceutical developments, consumer demand.
The vasomotor menopausal symptoms (vms) treatment market size is expected to see strong growth in the next few years. It will grow to $23.11 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to personalized medicine, non-hormonal innovations, nutritional and dietary interventions, telemedicine and digital health. Major trends in the forecast period include natural and alternative approaches, botanical and herbal remedies, menopause support groups, cognitive behavioral therapy (cbt).
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report
Scope Of Vasomotor Menopausal Symptoms (VMS) Treatment Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview
Market Drivers –
The increase in the menopause population is expected to propel the growth of the vasomotor menopausal symptoms treatment market going forward. Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is a significant life stage that typically occurs in women between the ages of 45 and 55, with the average age being around 51. The rising number of menopausal women, which demands treatment for hot flashes and vaginal dryness globally, is one of the primary factors pushing the growth of vasomotor menopausal symptoms (VMS) treatment. For instance, in November 2022, according to the Cuyuna Regional Medical Center, a US-based organization, estimated that by 2025, 1.1 billion women will be menopausal due to women living longer. Moreover, the population of menopausal will be increased by 1.6% annually until 2060. Therefore, the increase in the menopause population is driving the growth of the vasomotor menopausal symptoms treatment market.
Market Trends –
Major companies operating in the vasomotor menopausal symptoms treatment market are developing products such as Veozah and getting approvals to provide new treatment options and meet unmet medical needs for patients. The approval of new drugs for menopause provides improved efficacy and safety compared to existing treatments. For instance, in May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval for Veozah (fezolinetant) 45 mg once daily from the Food and Drug Administration (FDA), a US-based federal agency for the treatment of menopausal vasomotor symptoms (VMS), which range from mild to severe. It is the first nonhormonal neurokinin 3 (NK3) receptor antagonist to be authorized for treating menopausal-related VMS. It is a hormone-free option that blocks a pathway in the brain that helps regulate these symptoms. It provides an alternative treatment option for women experiencing these symptoms, particularly those who cannot or prefer not to use hormone therapy. The approval of Veozah highlights its potential as a new drug for managing menopausal symptoms.
The vasomotor menopausal symptoms (vms) treatment market covered in this report is segmented –
1) By Drug Class: Antidepressants; Fluoxetine; Paroxetine; Sertraline; Hormone Therapy; Anticonvulsant; Phenytoin; Phenobarbital; Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Get an inside scoop of the vasomotor menopausal symptoms (vms) treatment market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp
Regional Insights –
North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2023. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies –
Major players in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.
Table of Contents
1. Executive Summary
2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Report Structure
3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends And Strategies
4. Vasomotor Menopausal Symptoms (VMS) Treatment Market – Macro Economic Scenario
5. Vasomotor Menopausal Symptoms (VMS) Treatment Market Size And Growth
…..
27. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Explore Related Our Reports
https://topprnews.com/iron-deficiency-injectable-market-overview/
https://topprnews.com/pituitary-dwarf-treatment-market-growth/
https://topprnews.com/global-tempered-glass-cutting-machine-market-share/
https://goodprnews.com/global-iron-deficiency-injectable-market-overview/
https://goodprnews.com/pituitary-dwarf-treatment-market-driver/
https://goodprnews.com/global-tempered-glass-cutting-machine-market-overview/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
